Boston Scientific (NYSE:BSX) Sees Optimistic Price Target from Raymond James

Jayson Bedford from Raymond James sets a price target of $121 for Boston Scientific (NYSE:BSX), indicating a potential increase of approximately 16.57%. Quarterly earnings are expected to be $0.72 per share, with revenues forecasted at $4.89 billion, showing significant year-over-year growth. The stock receives an average brokerage recommendation (ABR) of 1.13, suggesting strong confidence from analysts and a positive market sentiment towards Boston Scientific.

Boston Scientific (NYSE:BSX) is a leading medical device company known for its innovative solutions in the healthcare sector. The company specializes in developing and manufacturing medical devices used in various interventional medical specialties. As of July 21, 2025, Jayson Bedford from Raymond James set a price target of $121 for BSX, suggesting a potential price increase of approximately 16.57% from its current price of $103.80. This optimistic outlook is supported by a strong buy rating from Raymond James, as reported by StreetInsider.

Boston Scientific is expected to report quarterly earnings of $0.72 per share, reflecting a 16.1% increase from the same period last year. Analysts forecast revenues of $4.89 billion, representing an 18.7% year-over-year growth. The stability in the consensus earnings per share (EPS) estimate over the past 30 days indicates that analysts have not revised their initial projections, which can be a significant indicator of potential investor behavior regarding the stock.

The upcoming earnings report, scheduled for release on July 23, is highly anticipated by the market. If Boston Scientific's actual results surpass the consensus estimates, the stock may experience an upward movement. Conversely, if the results fall short, the stock could decline. The sustainability of any immediate price changes and future earnings expectations will largely depend on the management's discussion of business conditions during the earnings call.

Wall Street analysts are showing optimism towards Boston Scientific, with the company receiving an average brokerage recommendation (ABR) of 1.13 on a scale from 1 to 5, where 1 indicates a Strong Buy. This rating is based on evaluations from 30 brokerage firms, with 27 of these recommendations being Strong Buy and two being Buy. This suggests that 90% of the analysts are highly confident in the stock's potential, reflecting a strong positive sentiment in the market towards Boston Scientific.

Currently, BSX is priced at $103.81, reflecting a slight increase of 0.17, or 0.16%. The stock has fluctuated between a low of $103.01 and a high of $104.96 today. Over the past year, BSX has reached a high of $107.53 and a low of $71.88. The company, listed on the NYSE, boasts a substantial market capitalization of approximately $153.58 billion. Today's trading volume for BSX stands at 4,015,860 shares.